Skip to main content

Tango Therapeutics, Inc. (TNGX)

NASDAQ: TNGX · IEX Real-Time Price · USD
12.73 -0.17 (-1.32%)
Oct 27, 2021 11:07 AM EDT - Market open
Market Cap1.15B
Revenue (ttm)22.42M
Net Income (ttm)n/a
Shares Out13.73M
EPS (ttm)-3.99
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,343
Open12.96
Previous Close12.90
Day's Range12.72 - 13.35
52-Week Range8.90 - 18.84
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About TNGX

Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients w...

IndustryBiotechnology
Founded2014
Employees86
Stock ExchangeNASDAQ
Ticker SymbolTNGX
Full Company Profile

Financial Performance

In 2020, TNGX's revenue was $7.66 million, a decrease of -68.94% compared to the previous year's $24.65 million. Losses were -$51.97 million, 268.7% more than in 2019.

Financial Statements

News

Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstract...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today annou...

3 weeks ago - Business Wire

Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm

Wedbush initiated coverage of Tango Therapeutics Inc (NASDAQ: TNGX) with an Outperform rating and a $12 price target.  Analyst Robert Driscoll believes Tango's unique synthetic lethality approach is dif...

1 month ago - Benzinga

Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine ...

Tango Therapeutics, a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, and BCTG Acquisition Corp. (Nasdaq: BCTG), a special purpose acquis...

6 months ago - Business Wire